Oruka Therapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $100.6M | $75.1M | $1.0M | $4.7M | $13.8M | $5.0M | $1.8M |
| SG&A Expense | — | $21.4M | $13.1M | $6.3M | $5.8M | $5.5M | $4.8M | $4.0M |
| Operating Income | — | $-122.1M | $-88.1M | $-7.3M | $-10.6M | $-19.3M | $-9.8M | $-5.8M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | $9.0K | $7.0K |
| Pretax Income | — | $-105.4M | $-83.7M | — | — | $-19.3M | $-9.7M | $-5.6M |
| Income Tax Expense | — | — | — | $0 | $0 | $0 | $-9.0K | $-167.0K |
| Net Income | — | $-105.4M | $-83.7M | $-5.3M | $-9.9M | $-19.3M | $-9.7M | $-5.5M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | — | $-3.87 | $-0.37 | $-0.69 | $-1.39 | $-2.07 | $-4.15 |
| EPS (Diluted) | — | — | $-3.87 | $-0.37 | $-0.69 | $-1.39 | $-2.07 | $-4.15 |
| Shares Outstanding (Basic) | 49.5M | 48.7M | 16.8M | 14.4M | 14.4M | 13.9M | 9.5M | 1.6M |
| Shares Outstanding (Diluted) | 49.5M | 48.7M | 16.8M | 14.4M | 14.4M | 13.9M | 9.5M | 1.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |